Company Encyclopedia
View More
name
Monopar Therapeutics
MNPR.US
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19.
1.946 T
MNPR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Monopar Therapeutics (NASDAQ:MNPR) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

    Monopar Therapeutics (NASDAQ:MNPR) reported quarterly earnings of ($0.48) per share, missing analysts' estimates by $0.02. The stock price fell $9.00 to $78.01. Analysts have mixed ratings, with some upgrading to 'strong-buy' and others downgrading. Major shareholder Tactic Pharma sold 550,229 shares. Institutional investors have made recent changes to their positions. Monopar's lead product, Validive, is in Phase 2b/3 trials for cancer treatment.

    Market Beat·
    US
    MNPR
    +2.96%
    Market Beat·
    US
    MNPR
    +2.96%

    BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

    BTIG analyst Jeet Mukherjee reiterated a Buy rating on Monopar Therapeutics Inc with a $104 price target. The stock closed at $87.01, and analysts have a consensus Strong Buy rating with a $110.33 price target, suggesting a 26.80% upside. Barclays also reiterated a Buy rating with a $125 target. Mukherjee, a 4-star analyst, has a 19.4% average return and a 71.43% success rate.

    Tip Ranks·
    US
    MNPR
    +2.96%
    Tip Ranks·
    US
    MNPR
    +2.96%

    Monopar Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MNPR
    +2.96%
    LB filings·
    US
    MNPR
    +2.96%

    Monopar Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MNPR
    +2.96%
    LB filings·
    US
    MNPR
    +2.96%

    Monopar Therapeutics reports third quarter net loss of $3.4 million

    Monopar Therapeutics Inc. reported a net loss of $3.4 million for Q3 2025, compared to $1.3 million in Q3 2024. The company holds $143.7 million in cash and investments. Recent developments include FDA clearance for MNPR-101-Lu, a Phase 1 trial, and preparations for a New Drug Application for ALXN1840. They also repurchased 550,229 shares for $35 million, following a public offering with net proceeds of $91.9 million.

    Reuters·
    US
    MNPR
    +2.96%
    Reuters·
    US
    MNPR
    +2.96%
    © 2025 Longbridge｜Disclaimer